How effective is tucatinib/tucatinib in breast cancer?

In 2020year4month,Tucatinib/Tucatinibis an oral HER2tyrosine Acid kinase inhibitor, available in combination with trastuzumab and capecitabine, for adult patients with advanced HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting. The patient's breast cancer is either unresectable (cannot be removed with surgery) or metastatic (the cancer has spread to other parts of the body). The new approval also includes patients with breast cancer that has spread to the brain. Tukysa is manufactured by Seattle Genetics.

In the HER2CLIMB study, 612 patients received tucatinib 300 mg orally twice daily plus trastuzumab and capecitabine or placebo pills (no active ingredients) plus trastuzumab and capecitabine. Patients receive treatment until disease progression or the patient develops unacceptable toxicity (side effects). The median duration of treatment in the Tukysa group was 5.8 months (ranging from 3 days to 2.9 years). The primary efficacy outcome measure was progression-free survival (PFS). Patients who received trastuzumab (Herceptin) and capecitabine (Xeloda) plus Tukysa had a significantly reduced risk of cancer progression (cancer growth or spread) or death (progression-free survival) by 46% compared with the group who received trastuzumab and capecitabine plus placebo. The median time to progression-free was 7.8 months in the tucatinib group and 5.6 months in the placebo group. Additionally, patients with brain metastases (cancer that has spread to the brain) also had a significantly reduced risk of cancer progression or death by 52%. Tucatinib has helped people live longer, with a median overall survival of 21.9 months (range 18.3 to 31 months), while trastuzumab has helped people live longer. The median overall survival for mAb and capecitabine + placebo was 17.4 months (range, 13.6 to 19.9months). The median overall survival was calculated as half of the people taking tucatinib lived more than 21.9 months and the other half lived less than 21.9 months. The addition of tucatinib significantly reduced the risk of death (overall survival) by 34% compared with trastuzumab and capecitabine + placebo. The median duration of response was 8.3 months (ranging from 6.2 months to 9.7 months) in the tucatinib group who received trastuzumab and capecitabine +The median duration of response with placebo treatment was 6.3 months (ranging from 5.8 months to 9.8 months). There is a generic version of this drug in Bangladesh. The retail price of Everest Pharmaceuticals in Bangladesh is about 150mg30 tablets6000 yuan. The retail price of Ziska Pharmaceuticals in Bangladesh is around 4,500 yuan for 150 mg 30 tablets. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.